Healthcare / Drug Manufacturers - GeneralBSE
$2731.60
-55.85 (-2.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-419.3M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16.9B
P/E
35.1x
↑EV/EBITDA
20.5x
↑ROE
14.6%
↑Gross Margin
52.2%
↑Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+22.3%
FCF CAGR
—
FCF margin
-9.3%
FCF / Net income
-0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.01B · net income $481.3M · FCF $-465.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.01B | $5.01B | $3.68B | $3.34B | $2.74B |
| Net Income | $481.3M | $481.3M | $211.2M | $413.2M | $205.0M |
| EBITDA | $874.2M | $874.2M | $425.0M | $674.0M | $398.5M |
| EPS | 77.90 | 77.90 | 34.19 | 66.88 | 33.18 |
| Gross Margin | 52.2% | 52.2% | 50.5% | 52.4% | 48.7% |
| Operating Margin | 10.6% | 10.6% | 5.8% | 12.6% | 8.7% |
| Net Margin | 9.6% | 9.6% | 5.7% | 12.4% | 7.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.27 | 0.13 | 0.15 |
| Current Ratio | 1.84 | 1.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-465.3M | $-465.3M | $-419.3M | $-80.6M | $38.8M |
| Returns | |||||
| ROE | 14.6% | 14.6% | 7.5% | 15.7% | 9.2% |
| Valuation | |||||
| P/E | 35.12 | 35.12 | 32.39 | 33.58 | 40.99 |
| EV/EBITDA | 20.51 | 20.51 | 17.90 | 21.08 | 21.70 |
| P/B | 5.13 | 5.13 | 2.42 | 5.28 | 3.78 |
| Growth & Yield | |||||
| Revenue Growth | 36.0% | 36.0% | 10.4% | 22.0% | — |
| EPS Growth | 127.8% | 127.8% | -48.9% | 101.6% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.0%
EPS terminal req.
$242.38
Spread vs growth
81.9%
5Y implied EPS CAGR
30.4%
EPS terminal req.
$293.28
Spread vs growth
97.5%
10Y implied EPS CAGR
19.7%
EPS terminal req.
$472.34
Spread vs growth
108.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+117.0%
Start / end P/E
36.8x → 35.1x
EPS bridge
34.19 → 77.90
Residual
-6.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.